| Company Name | Therapeutic Focus; Treatment Type | Underwriters | IPO Date | Offer Price to the Public | Aggregate Offering Raise | Original Price Range |
|---|---|---|---|---|---|---|
| Acrivon Therapeutics (NASDAQ: ACRV) | Precision Oncology | Jefferies, Cowen & Co., Piper Sandler | 11/14/2022 S-1 | $12.50 | $94.38 million | $16 – $18 |
| Prime Medicine (NASDAQ: PRME) | Gene Editing | JPMorgan, Goldman Sachs, Jefferies, Morgan Stanley | 10/19/2022 S-1 | $17.00 | $175 million | $16 – $18 |
| Third Harmonic Bio (NASDAQ: THRD) | Dermal, Respiratory and Gastrointestinal Diseases; Small Molecules | Morgan Stanley, Jefferies, Cowen & Co., LifeSci Capital | 09/14/2022 S-1 | $17.00 | $185.3 million | $16 – $18 |
| PepGen Inc. (NASDAQ: PEPG) | Neuromuscular and Neurologic Diseases; Therapeutics | BofA Securities, Stifel, SVB Securities, Wedbush Securities | 05/05/2022 S-1 | $12.00 | $108 million | $13 – $15 |
| AN2 Therapeutics (NASDAQ: ANTX) | Rare, Chronic and Serious Infectious Diseases; Therapeutics | Oppenheimer & Co., Cowen & Co., SVB Leerink, Evercore | 03/24/2022 S-1 | $15.00 | $69 million | $14 – $16 |
| Arcellx, Inc. (NASDAQ: ACLX) | Cancer; Cell Therapies | Barclays Capital, BofA Securities, SVB Leerink, William Blair & Co. | 02/04/2022 S-1 | $15.00 | $142.31 million | $15 – $17 |
| Vigil Neuro (NASDAQ: VIGL) | Neurodegenerative Diseases; Cell Therapies | Morgan Stanley, Jefferies, Stifel, Guggenheim | 01/11/2022 S-1 | $14.00 | $98 million | $14 – $16 |
| Amylyx Pharmaceuticals (NASDAQ: AMLX) | Neurodegenerative Diseases; Therapeutics | Evercore, Goldman Sachs, H.C. Wainwright, SVB Leerink | 01/07/2022 S-1 | $19.00 | $190 million | $18 – $20 |
| Cincor Pharma (NASDAQ: CINC) | Neurodegenerative Diseases; Therapeutics | Evercore, Jefferies, Morgan Stanley, Oppenheimer | 01/06/2022 S-1 | $17.00 | $193.60 million | $15 – $17 |
| Company Name | Therapeutic Focus; Treatment Type | Underwriters | IPO Date | Offer Price to the Public | Aggregate Offering Raise | Original Price Range |
|---|---|---|---|---|---|---|
| Acrivon Therapeutics (NASDAQ: ACRV) | Precision Oncology | Jefferies, Cowen & Co., Piper Sandler | 11/14/2022 S-1 | $12.50 | $94.38 million | $16 – $18 |
| Prime Medicine (NASDAQ: PRME) | Gene Editing | JPMorgan, Goldman Sachs, Jefferies, Morgan Stanley | 10/19/2022 S-1 | $17.00 | $175 million | $16 – $18 |
| Third Harmonic Bio (NASDAQ: THRD) | Dermal, Respiratory and Gastrointestinal Diseases; Small Molecules | Morgan Stanley, Jefferies, Cowen & Co., LifeSci Capital | 09/14/2022 S-1 | $17.00 | $185.3 million | $16 – $18 |
| PepGen Inc. (NASDAQ: PEPG) | Neuromuscular and Neurologic Diseases; Therapeutics | BofA Securities, Stifel, SVB Securities, Wedbush Securities | 05/05/2022 S-1 | $12.00 | $108 million | $13 – $15 |
| AN2 Therapeutics (NASDAQ: ANTX) | Rare, Chronic and Serious Infectious Diseases; Therapeutics | Oppenheimer & Co., Cowen & Co., SVB Leerink, Evercore | 03/24/2022 S-1 | $15.00 | $69 million | $14 – $16 |
| Arcellx, Inc. (NASDAQ: ACLX) | Cancer; Cell Therapies | Barclays Capital, BofA Securities, SVB Leerink, William Blair & Co. | 02/04/2022 S-1 | $15.00 | $142.31 million | $15 – $17 |
| Vigil Neuro (NASDAQ: VIGL) | Neurodegenerative Diseases; Cell Therapies | Morgan Stanley, Jefferies, Stifel, Guggenheim | 01/11/2022 S-1 | $14.00 | $98 million | $14 – $16 |
| Amylyx Pharmaceuticals (NASDAQ: AMLX) | Neurodegenerative Diseases; Therapeutics | Evercore, Goldman Sachs, H.C. Wainwright, SVB Leerink | 01/07/2022 S-1 | $19.00 | $190 million | $18 – $20 |
| Cincor Pharma (NASDAQ: CINC) | Neurodegenerative Diseases; Therapeutics | Evercore, Jefferies, Morgan Stanley, Oppenheimer | 01/06/2022 S-1 | $17.00 | $193.60 million | $15 – $17 |